Abstract
The COVID-19 pandemic that swiped across the globe led many countries to apply unprecedented nationwide restrictions and control measures. Analyzing aggregate and anonymized mobility data from the cell-phone devices of>3 million users in Israel, we identified that poorer regions exhibited lower and slower compliance with the restrictions. We integrated these mobility patterns into age-, risk- and region-structured transmission model, and showed how we can explain the spatiotemporal dynamics of 250 regions covering Israel. Model projections suggest that applying localized and temporal interventions that focus on high-risk groups can substantially reduce mortality, particularly in poorer regions, while enabling daily routine for a vast majority of the population. These trends were consistent across vast ranges of epidemiological parameters, possible seasonal forcing, and even when we assumed that vaccination would be commercially available in 1-3 years. Our methodology can help policymakers worldwide identify hotspots and apply designated strategies against future COVID-19 outbreaks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Israel Science Foundation (grant No. 3409/19), within the Israel Precision Medicine Partnership program. The Zimin Institute for Engineering Solutions Advancing Better Lives
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We hereby declare that the IRB chair of Tel Aviv University, Prof. Meir Lahav, determined on March 24, 2020, that there is no need for an IRB approval for this study. We also received consent from the data provider to use the aggregated and anonymized human mobility data in the way it is used in our study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available upon request